Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328726 · ClinicalTrials.gov registry record · Phase 1
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Gan and Lee Pharmaceuticals, U.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05328726 is a Phase 1 study of Diabetes Mellitus, Type 2 that has completed, run by Gan and Lee Pharmaceuticals, U. The registered enrollment target is 24 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05328726, a Phase 1 study of Diabetes Mellitus, Type 2, has completed, sponsored by Gan and Lee Pharmaceuticals, U.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Single ascending dose first time in human study for GZR18 in healthy subjects
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GZR-18
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2023-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328726
The ClinicalTrials.gov registry entry for NCT05328726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Gan and Lee Pharmaceuticals, U, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05328726 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT05328726 about?
NCT05328726 is a clinical study titled "Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects". Single ascending dose first time in human study for GZR18 in healthy subjects
What is the current status of trial NCT05328726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-03-08. Estimated completion is 2023-03-09.
What conditions does trial NCT05328726 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05328726?
The interventions under investigation include: Placebo (OTHER), GZR-18 (DRUG).
Who is sponsoring clinical trial NCT05328726?
This trial is sponsored by Gan and Lee Pharmaceuticals, U, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05328726 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.